DR. JUAN CARLOS MALPICA-SANTIAGO M.D.
Prescription History 1386959633
Internal Medicine - Pulmonary Disease in Guaynabo, PR

NPI Status: Active since August 11, 2010

Contact Information

101 AVE SAN PATRICIO
SUITE 1240
GUAYNABO, PR
ZIP 00968
Phone: (787) 508-5445
Fax: (787) 545-5127

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JUAN CARLOS MALPICA-SANTIAGO M.D., an active Pulmonary Disease specialist practicing in Guaynabo, PR. Our medical registry currently tracks 21 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,935 documented patient claims. Among these therapy options, the most frequently utilized medication is Fluticasone Propionate, which accounts for 448 claims alone.


Adempas

Generic Formulation: RiociguatSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
PR State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills95.0
Peer Average Days Supply2,823
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.0% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $421,191.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,162.23

State Avg Cost Per Claim

$12,366.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Riociguat is used to treat high blood pressure in the lungs (pulmonary hypertension). It can also be used to treat a certain type of high blood pressure in the lungs caused by blood clots (chronic thromboembolic pulmonary hypertension) when surgery has not been fully successful or is impossible. Riociguat works by relaxing and widening the blood vessels in your lungs so blood can flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 61
30-Day Fills 62.7
Days Supply 1,485
PR State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills96.5
Peer Average Days Supply2,524
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,768.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.38

State Avg Cost Per Claim

$46.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Ambrisentan

Generic Formulation: AmbrisentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
PR State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.4
Peer Average Days Supply636
Conservative Utilization

This provider writes prescriptions for this formulation 47.6% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,809.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,528.16

State Avg Cost Per Claim

$3,343.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ambrisentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, thereby helping to decrease the blood pressure in the lungs, slow the worsening of symptoms, and improve your ability to exercise.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
PR State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills44.7
Peer Average Days Supply1,341
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.1% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,417.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$467.65

State Avg Cost Per Claim

$468.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Atrovent Hfa

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 340
PR State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills32.9
Peer Average Days Supply885
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,050.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$465.40

State Avg Cost Per Claim

$468.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 332
30-Day Fills 478.3
Days Supply 14,220
PR State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills85.4
Peer Average Days Supply2,476
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 418.8% higher than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,279.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.93

State Avg Cost Per Claim

$26.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azelastine-Fluticasone

Generic Formulation: Azelastine/FluticasoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 660
PR State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills35.3
Peer Average Days Supply1,044
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,569.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$142.77

State Avg Cost Per Claim

$166.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to relieve seasonal allergy symptoms of the nose such as stuffy/runny nose, itching, sneezing, and post-nasal drip. It contains 2 drugs. Azelastine is an antihistamine that works by blocking certain natural substances called histamines that are responsible for allergic symptoms. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) in the nasal passages.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 209
PR State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills49.8
Peer Average Days Supply239
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $942.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.94

State Avg Cost Per Claim

$8.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 215
30-Day Fills 221.0
Days Supply 6,630
PR State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills67.9
Peer Average Days Supply2,037
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 230.8% higher than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $88,625.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$412.21

State Avg Cost Per Claim

$404.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
PR State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply839
Conservative Utilization

This provider writes prescriptions for this formulation 30.8% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,537.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$640.96

State Avg Cost Per Claim

$667.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 54.0
Days Supply 1,620
PR State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills48.2
Peer Average Days Supply1,445
Conservative Utilization

This provider writes prescriptions for this formulation 28.2% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,726.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$347.36

State Avg Cost Per Claim

$355.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Famotidine

Generic Formulation: FamotidineSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 42.0
Days Supply 1,155
PR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply377
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 111.8% higher than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $281.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.82

State Avg Cost Per Claim

$4.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Therapeutic Applications

Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Famotidine belongs to a class of drugs known as H2 blockers. This medication is also available without a prescription. It is used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion). If you are taking this medication for self-treatment, it is important to read the manufacturer's package instructions carefully so you know when to consult your doctor or pharmacist.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 25.0
Days Supply 750
PR State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills46.4
Peer Average Days Supply1,387
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.5% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,723.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$248.22

State Avg Cost Per Claim

$313.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 448
30-Day Fills 517.0
Days Supply 15,495
PR State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills113.5
Peer Average Days Supply3,377
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 381.7% higher than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,313.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.09

State Avg Cost Per Claim

$12.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Opsumit

Generic Formulation: MacitentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
PR State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills64.9
Peer Average Days Supply1,947
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.4% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $206,609.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,153.48

State Avg Cost Per Claim

$11,419.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Macitentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, which helps decrease the blood pressure in the lungs, and reduces the risk of worsening of symptoms and hospital stays due to the disease.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 69
30-Day Fills 71.0
Days Supply 695
PR State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills62.0
Peer Average Days Supply1,242
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $270.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.92

State Avg Cost Per Claim

$5.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 96
30-Day Fills 96.0
Days Supply 2,880
PR State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills77.2
Peer Average Days Supply2,314
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.7% more claims than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $50,004.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$520.88

State Avg Cost Per Claim

$519.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 59
30-Day Fills 59.0
Days Supply 1,770
PR State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills72.3
Peer Average Days Supply2,168
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,865.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$455.34

State Avg Cost Per Claim

$478.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 183
30-Day Fills 261.0
Days Supply 7,830
PR State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills68.6
Peer Average Days Supply2,057
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 200.0% higher than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67,640.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$369.62

State Avg Cost Per Claim

$389.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 208
30-Day Fills 220.0
Days Supply 6,598
PR State Average Benchmarks
Peer Average Claims75.0
Peer Average 30-Day Fills78.7
Peer Average Days Supply2,356
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 177.3% higher than the standard regional baseline profile for PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $137,723.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$662.13

State Avg Cost Per Claim

$653.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
PR State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills37.5
Peer Average Days Supply1,124
Conservative Utilization

This provider writes prescriptions for this formulation 34.3% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,636.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$201.60

State Avg Cost Per Claim

$225.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JUAN CARLOS MALPICA-SANTIAGO M.D. provides transparency into local medical care patterns within Guaynabo, PR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.